Repligen Co. (NASDAQ:RGEN) Shares Sold by Corebridge Financial Inc.

Corebridge Financial Inc. reduced its holdings in Repligen Co. (NASDAQ:RGEN - Free Report) by 4.3% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 59,054 shares of the biotechnology company's stock after selling 2,660 shares during the period. Corebridge Financial Inc. owned approximately 0.11% of Repligen worth $8,500,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently made changes to their positions in the company. Signaturefd LLC lifted its holdings in shares of Repligen by 172.2% in the 4th quarter. Signaturefd LLC now owns 196 shares of the biotechnology company's stock valued at $28,000 after acquiring an additional 124 shares during the last quarter. Resources Management Corp CT ADV bought a new stake in shares of Repligen in the 3rd quarter valued at approximately $37,000. Quarry LP boosted its holdings in shares of Repligen by 796.7% in the 3rd quarter. Quarry LP now owns 269 shares of the biotechnology company's stock worth $40,000 after purchasing an additional 239 shares during the period. UMB Bank n.a. boosted its holdings in shares of Repligen by 49.1% in the 4th quarter. UMB Bank n.a. now owns 334 shares of the biotechnology company's stock worth $48,000 after purchasing an additional 110 shares during the period. Finally, Global Retirement Partners LLC increased its position in shares of Repligen by 54.0% during the 4th quarter. Global Retirement Partners LLC now owns 368 shares of the biotechnology company's stock valued at $53,000 after purchasing an additional 129 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Repligen

In other Repligen news, Director Margaret Pax acquired 250 shares of the firm's stock in a transaction dated Monday, March 17th. The stock was purchased at an average price of $150.69 per share, for a total transaction of $37,672.50. Following the acquisition, the director now owns 1,043 shares in the company, valued at approximately $157,169.67. This trade represents a 31.53 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 1.20% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on RGEN shares. JPMorgan Chase & Co. raised their price target on Repligen from $190.00 to $200.00 and gave the stock an "overweight" rating in a research report on Friday, February 21st. Canaccord Genuity Group started coverage on shares of Repligen in a report on Tuesday, December 17th. They issued a "hold" rating and a $165.00 target price for the company. Evercore ISI started coverage on shares of Repligen in a report on Tuesday, March 18th. They set an "in-line" rating and a $155.00 price target on the stock. Canaccord Genuity Group raised their price objective on shares of Repligen from $165.00 to $170.00 and gave the stock a "hold" rating in a research note on Friday, February 21st. Finally, HC Wainwright restated a "buy" rating and set a $180.00 target price on shares of Repligen in a research report on Friday, February 21st. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Hold" and a consensus target price of $178.64.

Repligen Stock Up 1.0 %

Repligen stock traded up $1.26 during midday trading on Tuesday, hitting $128.50. 748,822 shares of the company's stock were exchanged, compared to its average volume of 676,999. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.76 and a current ratio of 10.44. The company has a market cap of $7.22 billion, a PE ratio of -251.96, a P/E/G ratio of 4.54 and a beta of 0.95. The firm has a 50-day moving average of $152.75 and a two-hundred day moving average of $148.00. Repligen Co. has a 12 month low of $113.50 and a 12 month high of $182.52.

Repligen (NASDAQ:RGEN - Get Free Report) last issued its quarterly earnings data on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.41 by $0.03. The company had revenue of $167.55 million for the quarter, compared to analyst estimates of $167.58 million. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. As a group, analysts expect that Repligen Co. will post 1.72 earnings per share for the current fiscal year.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.